Related Experiment Video
Updated: Jul 11, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease
Hindupur K Anandatheerthavarada1, Latha Devi
1Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104, USA ann1234@vet.upenn.edu
Summary
Mitochondrial dysfunction is central to Alzheimer's disease (AD) pathogenesis. This review examines how amyloid precursor protein (APP) and beta-amyloid (Abeta) accumulation within mitochondria drives this dysfunction.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Mitochondrial dysfunction is a key factor in Alzheimer's disease (AD) development.
- Mitochondria are vital for cellular functions including calcium homeostasis, signal transduction, and apoptosis.
- The precise mechanisms linking mitochondrial dysfunction to AD pathogenesis remain unclear.
Purpose of the Study:
- To review the transport mechanisms of amyloid precursor protein (APP) and beta-amyloid (Abeta) into mitochondria.
- To explore the pathological implications of APP and Abeta accumulation within the mitochondrial compartment in AD.
- To elucidate the role of mitochondrial APP and Abeta in AD-related mitochondrial dysfunction.
Main Methods:
- Literature review of existing studies on mitochondrial transport of APP and Abeta.
- Analysis of evidence implicating APP and Abeta in mitochondrial dysfunction in Alzheimer's disease.
- Synthesis of current understanding regarding the pathological consequences of mitochondrial APP/Abeta.
Main Results:
- Accumulation of full-length APP and its cleavage product Abeta has been observed within mitochondria.
- Evidence suggests that mitochondrial APP and Abeta accumulation directly impairs vital mitochondrial functions.
- The transport and pathological role of APP/Abeta in mitochondrial dysfunction in AD are increasingly recognized.
Conclusions:
- Mitochondrial accumulation of APP and Abeta is a significant contributor to Alzheimer's disease pathogenesis.
- Understanding the mitochondrial transport of APP and Abeta is crucial for deciphering AD pathophysiology.
- Targeting mitochondrial APP/Abeta pathways may offer novel therapeutic strategies for Alzheimer's disease.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:39Mitochondrial Precursor Proteins
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial precursors...
Most of the mitochondrial precursors...